A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Samsung Bioepis Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged 18 years or older
Diagnosed as NSCLC stage II-IIIA (staging should be confirmed after surgery)
Have completely removed all of the cancer from the body surgically
Have been received 3 or 4 cycles of platinum-based chemotherapy after surgery
You may not be if
Have received anti-cancer therapy before surgery
Have or had autoimmune disease in past 5 years
Clareo Health | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
